A biotech startup, incubated at the ASPIRE-Technology Business Incubator (ASPIRE-TBI), University of Hyderabad (UoH), may have found a treatment for Covid-19 that is based on a human umbilical cord (UC) tissue harvested and clinically processed adult Mesenchymal Stem Cells (MSCs).
Transcell Oncologics, which uses cell-based products and solutions to treat cancer and other chronic diseases, has now developed a proprietary cell-based platform technology ‘HEMATO UC-MSCs’ with anti-cytokine storm properties, anti-inflammatory attributes and repairing abilities for Covid-19 treatment.
In extreme Covid-19 cases, patients have high levels of immune system proteins called cytokines in their blood. With the excessive production of pro-inflammatory cytokines, so-called “cytokine storm”, the body starts to attack its own cells and tissues rather than just fighting off the virus resulting in multi-organ failure and death.
The treatment significantly decreases the cytokines, improving patient survival and time to recovery. The research recommends HEMATO UC-MSCs to be administered as “two intravenous infusions, at a dose of 100 million cells per infusion, given 72 hours apart to the Covid patients”.
“The advantage of the therapy is this new way of curing covid patients in real time to SAVE them and NOT to treat the symptoms alone,” founder-CEO Subhadra Dravida said in a statement.
“Also, if HEMATO UC-MSCs are administered as the first line of treatment followed by concomitant steps to alleviate the associated symptoms in a traditional way, Covid deaths can be dodged.”
Dravida said that this stem-cell based treatment is already being used by several hospitals in Hyderabad and Telangana to save Covid-19 patients, while hospitals in other cities are also gearing up to start the treatment.
It can be delivered across the country within 48 hours and has been specially treated for storage under 2-8 degree Celsius refrigerated conditions for ease of use by the practitioners within 72 hours.